Innate Pharma is a global, clinical stage oncology-focused biotech company. In December 2020, Innate decided to return Lumoxiti commercial rights to AstraZeneca and to re-focus investments in its R&D portfolio consisting of product candidates, some of which Innate is co-developing, in the early stages of clinical development and preclinical programs.
Company profile
Ticker
IPHA, IPHYF
Exchange
Website
CEO
Mondher Mahjoubi
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...
Former names
Innate Pharma, SA
SEC CIK
IPHA stock data
Analyst ratings and price targets
Latest filings (excl ownership)
6-K
Innate Pharma S.a. 6-K
25 Jan 23
6-K
Innate Pharma S.a. 6-K
17 Jan 23
6-K
Innate Pharma S.a. 6-K
19 Dec 22
6-K
Innate Pharma S.a. 6-K
12 Dec 22
6-K
Innate Pharma S.a. 6-K
12 Dec 22
6-K
Innate Pharma S.a. 6-K
9 Dec 22
6-K
Innate Pharma S.a. 6-K
1 Dec 22
6-K
Innate Pharma S.a. 6-K
14 Nov 22
6-K
Innate Pharma S.a. 6-K
7 Nov 22
6-K
Innate Pharma S.a. 6-K
4 Nov 22
Financial summary
| Quarter (USD) | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
Institutional ownership, Q3 2022
12.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 12 |
| Opened positions | 1 |
| Closed positions | 3 |
| Increased positions | 3 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 40.98 mm |
| Total shares | 9.88 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Bpifrance Participations | 8.95 mm | $39.12 mm |
| BLK Blackrock | 482.65 k | $965.00 k |
| Optiver Holding B.V. | 185.31 k | $371.00 k |
| BAC Bank Of America | 164.78 k | $330.00 k |
| MS Morgan Stanley | 56.85 k | $114.00 k |
| Two Sigma Investments | 18.79 k | $38.00 k |
| Millennium Management | 14.63 k | $29.00 k |
| UBS UBS Group AG - Registered Shares | 4.51 k | $9.00 k |
| Steward Partners Investment Advisory | 500.00 | $1.00 k |
| RY Royal Bank Of Canada | 177.00 | $0.00 |
News
Innate Pharma Announces HSR Clearance Regarding Expansion Of Its Collaboration With Sanofi On NK Cell Engagers
25 Jan 23
Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session
27 Dec 22
US Stocks Open Lower; Nasdaq Slides Over 100 Points
27 Dec 22
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
27 Dec 22
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
19 Dec 22
Press releases
Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers
25 Jan 23
Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology
16 Jan 23
Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology
19 Dec 22
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
19 Dec 22
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022
10 Dec 22